Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming
Publishing timestamp: 2024-03-19 10:08:05
Summary
FDA approved Madrigal Pharmaceuticals' drug "Rezdiffra" for the treatment of nonalcoholic steatohepatitis (NASH) with moderate-to-advanced liver scarring. The approval is significant as it addresses a common and serious liver disease with a potentially large market. Other companies are also developing treatments for NASH, with a focus on GLP-1s. Generative artificial intelligence was a dominant topic at the HIMSS conference, particularly in the context of ambient clinical documentation tools that aim to reduce doctors' administrative workloads.
Sentiment: POSITIVE
Tickers: LLY, VKTX, CRM, MRK, MDGL, ETNB, NVO, ZEAL-DK, ALGS, MSFT, AKRO, GEHC, GOOGL, NOVO.B-DK,
Keywords: madrigal pharmaceuticals inc, business news, aligos therapeutics inc, microsoft corp, science, eli lilly and co, biotech and pharmaceuticals, viking therapeutics inc, salesforce inc, 89bio inc, zealand pharma a/s, novo nordisk a/s, health care industry, ge healthcare technologies inc, united states, alphabet inc, akero therapeutics inc, merck & co inc,